Refractory celiac disease

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 3, 2014, Pages 323-328

  Malamut, Georgia ^a,b   Cellier, Christophe ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

aberrant intraepithelial lymphocytes; clonal rearrangement; refractory celiac disease; T cell receptor; ulcerative jejunitis

Indexed keywords

CELIAC DISEASE; DIET, GLUTEN-FREE; DISEASE MANAGEMENT; HUMANS; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; SURVIVAL RATE; TREATMENT FAILURE;

EID: 84894144920     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.887438     Document Type: Review

References (48)

1. West J. Celiac disease and its complications: a time traveller's perspective. Gastroenterology 2009;136:32-4
2. Roshan B, Leffler DA, Jamma S, et al. The incidence and clinical spectrum of refractory celiac disease in a north american referral center. Am J Gastroenterol 2011;106:923-8
3. Rubio-Tapia A, Kelly DG, Lahr BD, et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009;136:99-107
4. Daum S, Ipczynski R, Schumann M, et al. High rates of complications and substantial mortality in both types of refractory sprue. Eur J Gastroenterol Hepatol 2009;21:66-70
5. Al-Toma A, Verbeek WH, Hadithi M, et al. Survival in refractory coeliac disease and enteropathy associated T cell lymphoma: retrospective evaluation of single centre experience. Gut 2007;56:1373-8
6. Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 2009;136: 81-90
7. Vahedi K, Mascart F, Mary JY, et al. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol 2003;98:1079-87
8. Akram S, Murray JA, Pardi DS, et al. Adult autoimmune enteropathy: mayo Clinic Rochester experience. Clin Gastroenterol Hepatol 2007;5:1282-90
9. Khokhar N, Gill ML. Tropical sprue: revisited. J Pak Med Assoc 2004;54:133-4
10. Malamut G, Verkarre V, Suarez F, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol 2010;105:2262-75
11. Green PH, Cellier C. Celiac disease. N Engl J Med 2007;357:1731-43
12. Cellier C, Patey N, Mauvieux L, et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 1998;114:471-81
13. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000;356:203-8
14. Daum S, Cellier C, Mulder CJ. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005;19:413-24
15. Perfetti V, Brunetti L, Biagi F, et al. TCRbeta clonality improves diagnostic yield of TCRgamma clonality in refractory celiac disease. J Clin Gastroenterol 2012;46: 675-9
16. Daum S, Wahnschaffe U, Glasenapp R, et al. Capsule endoscopy in refractory celiac disease. Endoscopy 2007;39:455-8
17. Barret M, Malamut G, Rahmi G, et al. Diagnostic yield of capsule endoscopy in refractory celiac disease. Am J Gastroenterol 2012;107(10):1546-53
18. Vakiani E, Arguelles-Grande C, Mansukhani MM, et al. Collagenous sprue is not always associated with dismal outcomes: a clinicopathological study of 19 patients. Mod Pathol 2010;23:12-26
19. Goerres MS, Meijer JW, Wahab PJ, et al. Azathioprine and prednisone combination therapy in refractory coeliac disease. Aliment Pharmacol Ther 2003;18:487-94
20. Verkarre V, Romana SP, Cellier C, et al. Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue. Gastroenterology 2003;125:40-6
21. Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis 2013;45: 377-84
22. Hoffmann M, Vogelsang H, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut 2003;52:347-51
23. Al-Toma A, Goerres MS, Meijer JW, et al. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathyassociated T-cell lymphoma. Clin Gastroenterol Hepatol 2006;4:315-19
24. Wijmenga C. Genetic and risk for associated autoimmune disorders and refractory coeliac disease. Mastering the coeliac condition; Florence, Italy; 2012
25. Mention JJ, Ben Ahmed M, Begue B, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003;125:730-45
26. Ciccocioppo R, Di Sabatino A, Parroni R, et al. Increased enterocyte apoptosis and Fas-Fas ligand system in celiac disease. Am J Clin Pathol 2001;115:494-503
27. Di Sabatino A, Ciccocioppo R, D'Alo S, et al. Intraepithelial and lamina propria lymphocytes show distinct patterns of apoptosis whereas both populations are active in Fas based cytotoxicity in coeliac disease. Gut 2001;49:380-6
28. Hue S, Mention JJ, Monteiro RC, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004;21:367-77
29. Malamut G, El Machhour R, Montcuquet N, et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest 2010;120: 2131-43
30. Holmes GK, Prior P, Lane MR, et al. Malignancy in coeliac disease-effect of a gluten free diet. Gut 1989;30:333-8
31. Doherty TM, Seder RA, Sher A. Induction and regulation of IL-15 expression in murine macrophages. J Immunol 1996;156: 735-41
32. Flamand L, Stefanescu I, Menezes J. Human herpesvirus-6 enhances natural killer cell cytotoxicity via IL-15. J Clin Invest 1996;97:1373-81
33. Vazquez N, Walsh TJ, Friedman D, et al. Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans. Infect Immun 1998;66:145-50
34. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999;17:19-49
35. Stene LC, Honeyman MC, Hoffenberg EJ, et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 2006;101:2333-40
36. Foxman EF, Iwasaki A. Genome-virome interactions: examining the role of common viral infections in complex disease. Nat Rev Microbiol 2011;9:254-64
37. Gough DJ, Messina NL, Clarke CJ, et al. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012;36:166-74
38. Colpitts SL, Stoklasek TA, Plumlee CR, et al. Cutting edge: the role of IFN-alpha receptor and MyD88 signaling in induction of IL-15 expression in vivo. J Immunol 2012;188:2483-7
39. Dafik L, Albertelli M, Stamnaes J, et al. Activation and inhibition of transglutaminase 2 in mice. PLoS One 2012;7(2):e30642
40. Dray X, Joly F, Lavergne-Slove A, et al. A severe but reversible refractory sprue. Gut 2006;55:1210-11
41. Al-Toma A, Goerres MS, Meijer JW, et al. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol 2006;4:1322-7
42. Al-Toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T-cells. Blood 2007;109(5): 2243-9
43. Tack GJ, Wondergem MJ, Al-Toma A, et al. Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy. Bone Marrow Transplant 2011; 46(6):840-6
44. Waldmann TA. Targeting the interleukin-15 system in rheumatoid arthritis. Arthritis Rheum 2005;52:2585-8
45. Yokoyama S, Perera PY, Waldmann TA, et al. Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. J Clin Immunol 2013;33:586-94
46. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012;64:617-29
47. Malamut G, Meresse B, Verkarre V, et al. Large granular lymphocytic leukemia: a treatable form of refractory celiac disease. Gastroenterology 2012;143:1470-2
48. Malamut G, Meresse B, Kaltenbach S, et al. Small intestinal CD4 T cell lymphoma: a heterogenous entity with common pathological features. Clin Gastroenterol Hepatol 2013. [Epub ahead of print]